November 01, 2017

Prenatal Genetic Testing: Where Algorithms May Fail

By Aubrey Haddach and Jeffrey Licitra

On the forefront of the much anticipated arrival of genomic medicine, the field of noninvasive prenatal genetic testing (NIPT) has lived up to its expectations as a game changer. NIPT is estimated to be worth $500 million in 2013, with potential to grow to 2.38 billion by 2022.1 NIPT not only has revolutionized access to prenatal testing for genetic disorders through a mere blood test, but it also is unique enough to defy classification by both intellectual property law and the existing Food and Drug Administration (FDA) regulatory framework.

Premium Content For:
  • Science and Technology Law Section
Join - Now